Nafamostat Mesylate Protects Against Acute Renal Ischemia–Reperfusion Injury by Alleviating Mitochondrial Dysfunction, Inhibiting Ferroptosis, and Regulating Proximal Tubular Cells: A Multi‐Omics Analysis
Therapeutic Apheresis and Dialysis · 2025
DOI: 10.1002/1744-9987.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Yu Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Clinical Research Center for Nephropathy/Metabolic Vascular Dis…. Hauptthemen laut MEDLINE: Reperfusion Injury, Acute Kidney Injury, Ferroptosis, Mitochondria. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Luzhou Science and Technology Bureau.
Abstract (Originalsprache)
Objective
The present study aims to explore the role of nafamostat mesylate (NM) in ischemia–reperfusion (I/R)‐induced acute kidney injury (AKI).
Methods
Twenty‐one male rats were randomly divided into three groups: sham, I/R, and I/ R + NM groups. Acute renal I/R injury models were created in the I/R and I/ R + NM groups by right nephrectomy and clamping the left renal pedicle for 45 min. Rats in the I/ R + NM group were intraperitoneally injected with 0.75 mg/kg of NM before modeling. Blood and kidney specimens were collected at 24 h after model establishment. RNA sequencing (RNA‐seq), KEGG and GO enrichment analyses, and single‐cell sequencing were carried out to investigate the related mechanisms.
Results
The pretreatment with NM improved renal function, reduced mitochondrial damage, suppressed the accumulation of reactive oxygen species, and inhibited ferroptosis. The RNA‐seq indicated that NM induced protection by upregulating fatty acids, inhibiting inflammation, and promoting DNA repair. Proximal tubular cells were mainly affected.
Conclusion
NM protects against AKI by reducing reactive oxygen species, upregulating fatty acids, and regulating ferroptosis signaling pathways in proximal tubular cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Affiliated Hospital of Southwest Medical University/Sichuan Clinical Research Center for Nephropathy/Metabolic Vascular Disease Key Laboratory, Luzhou, China.
- The Medical Center of Dujiangyan, Chengdu, China.
- Anatomy Teaching and Research Office of Southwest Medical University, Luzhou, China.
- Department of General Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
- Department of Nephrology, The First People's Hospital of Zigong, Zigong, China.
- Department of Urology, Affiliated Hospital of Southwest Medical University/Sichuan Clinical Research Center for Nephropathy/Metabolic Vascular Disease Key Laboratory, Luzhou, China.
Förderung
- Luzhou Science and Technology Bureau
Zitieren
APA
Wang, Y., Wu, Y., Li, H., Liu, J., Chen, B., Li, Y., Wang, Q., Zhang, D., Huang, L., Xing, H., Ou, S., Xue, L., & Wu, W. (2025). Nafamostat Mesylate Protects Against Acute Renal Ischemia–Reperfusion Injury by Alleviating Mitochondrial Dysfunction, Inhibiting Ferroptosis, and Regulating Proximal Tubular Cells: A Multi‐Omics Analysis. Therapeutic Apheresis and Dialysis. https://doi.org/10.1002/1744-9987.70112
Vancouver
Wang Y, Wu Y, Li H, Liu J, Chen B, Li Y, et al. Nafamostat Mesylate Protects Against Acute Renal Ischemia–Reperfusion Injury by Alleviating Mitochondrial Dysfunction, Inhibiting Ferroptosis, and Regulating Proximal Tubular Cells: A Multi‐Omics Analysis. Therapeutic Apheresis and Dialysis. 2025. doi:10.1002/1744-9987.70112
BibTeX
@article{Wang2025,
author = {Wang, Yu and Wu, Yuxuan and Li, Hongqian and Liu, Jiang and Chen, Bo and Li, Ying and Wang, Qiaoyu and Zhang, Dongmei and Huang, Lan and Xing, Huameng and Ou, Santao and Xue, Ling and Wu, Weihua},
title = {Nafamostat Mesylate Protects Against Acute Renal Ischemia–Reperfusion Injury by Alleviating Mitochondrial Dysfunction, Inhibiting Ferroptosis, and Regulating Proximal Tubular Cells: A Multi‐Omics Analysis},
journal = {Therapeutic Apheresis and Dialysis},
year = {2025},
doi = {10.1002/1744-9987.70112}
}
EUVIMED